Decoding adaptive-like γδ T-cell recognition in human herpesvirus infection
Year of award: 2026
Grantholders
Dr Fiyaz Mohammed
University of Birmingham, United Kingdom
Prof Benjamin Willcox
University of Birmingham, United Kingdom
Dr Heather Long
University of Birmingham, United Kingdom
Dr Ceri Fielding
Cardiff University, United Kingdom
Prof Steve Smerdon
University of Birmingham, United Kingdom
Prof Eddie Wang
Cardiff University, United Kingdom
Dr Carrie Willcox
University of Birmingham, United Kingdom
Prof Andrew Sewell
Cardiff University, United Kingdom
Project summary
Our work has revised understanding of human γδ T-cells, establishing that in addition to innate-like subsets, the compartment unexpectedly includes a major adaptive-like component. Adaptive-like γδ T-cells are an evolutionarily ancient, MHC-unrestricted arm that acts as ‘Nature’s CAR-T-cells’, driving protection against pathogens and tumours. However, an understanding of how changes denoting infection and cancer are ‘encoded’ in antigenic ligands, and how such alterations are ‘deciphered’ by the γδ-TCR - a holy grail in the field - is currently lacking. This proposal focusses a multidisciplinary collaborative team on tackling this challenge, exploiting Cytomegalovirus and Epstein Barr Virus as human models of microbial stress. Leveraging virology, γδ T-cell immunobiology, ligand identification, and molecular skillsets, we will define how γδ-TCRs sense virally-induced signatures of ‘altered-self’ and how this relates to γδ TCR-mediated recognition of ‘transformed-self’. Our programme will profoundly shift current paradigms of γδ T-cell immunobiology, establishing adaptive subsets as sophisticated sensors of stress-induced ligand alterations. Collectively, it will reveal new molecular targets, uncover distinct principles of TCR/ligand recognition, and define novel antigen-specific γδ-TCR clonotypes. In doing so, the outcomes will create a platform for development of new classes of γδ-TCR-based biotherapeutics and engineered cellular therapies with broad applicability for infection and cancer.